ノルウェー -
ノルウェー語 -
Statens legemiddelverk
asmanex twisthaler 400 mikrog
n.v. organon - kloosterstraat - mometasonfuroat - inhalasjonspulver - 400 mikrog
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
cytarabin fresenius kabi 100 mg/ ml
fresenius kabi norge as - cytarabin - injeksjons-/infusjonsvæske, oppløsning - 100 mg/ ml
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
flumazenil fresenius kabi 0.1 mg/ ml
fresenius kabi norge as - halden - flumazenil - injeksjonsvæske, oppløsning - 0.1 mg/ ml
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
flumazenil hameln 0.1 mg/ ml
hameln pharma plus gmbh - flumazenil - injeksjons-/infusjonsvæske, oppløsning - 0.1 mg/ ml
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
naloxon hameln 0.4 mg/ ml
hameln pharma gmbh - naloksonhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 0.4 mg/ ml
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
nexodal 0.4 mg/ ml
orpha-devel handels und vertriebs gmbh - naloksonhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 0.4 mg/ ml
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
ondansetron kalceks 2 mg/ ml
as kalceks - ondansetronhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
zanosar 1 g
esteve pharmaceuticals s.a.s. - streptozocin - pulver til konsentrat til infusjonsvæske, oppløsning - 1 g
ノルウェー -
ノルウェー語 -
Statens legemiddelverk
ondansetron hameln 2 mg/ ml
hameln pharma gmbh - ondansetronhydrokloriddihydrat - injeksjonsvæske, oppløsning - 2 mg/ ml
欧州連合 -
ノルウェー語 -
EMA (European Medicines Agency)
pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiske midler - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.